Internal Medicine, Hematology & Oncology · Fresno, CA
NPI
1417927054
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
7130 N Millbrook Ave
Fresno, CA, 93720
Phone (559) 326-1222
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.9M
384,987 services
Medicare patients, 2024
1,106
Average age 75
Drug cost, 2024
$7.9M
2,244 prescriptions
Company payments, 2025
$655
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ravi D Rao was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 74,400 times for 59 patients. In total Ravi D Rao billed 384,987 services in 209 codes, and Medicare paid $7.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 74,400 | 59 | $2.33 | $173K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 36,000 | 35 | $0.85 | $31K |
| J9299 Injection, nivolumab, 1 mg | Office | 26,980 | 31 | $24.63 | $664K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 13,200 | 19 | $44.56 | $588K |
| J0897 Injection, denosumab, 1 mg | Office | 13,080 | 70 | $20.06 | $262K |
| J0185 Injection, aprepitant, 1 mg | Office | 12,480 | 48 | $1.35 | $17K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 8,100 | 11 | $38.96 | $316K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 8,000 | 76 | $15.74 | $126K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 7,550 | 69 | $0.10 | $783 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 6,500 | 35 | $4.41 | $29K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 6,420 | 20 | $51.23 | $329K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 5,800 | 12 | $0.05 | $309 |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,962 | 13 | $0.08 | $388 |
| 36415 Venipuncture Blood Collection | Office | 3,912 | 758 | $8.64 | $34K |
| 85025 Blood Count | Office | 3,871 | 753 | $7.59 | $29K |
By year: 2022 $8.2M for 639,300 services; 2023 $9.6M for 627,243 services; 2024 $7.9M for 384,987 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,912 | 758 | $8.64 | $34K |
| 85025 Blood Count | 3,871 | 753 | $7.59 | $29K |
| 80053 Clinical Chemistry | 2,942 | 747 | $10.32 | $30K |
| 83550 Clinical Chemistry | 1,565 | 535 | $8.54 | $13K |
| 83540 Clinical Chemistry | 1,563 | 535 | $6.32 | $9,884 |
| 82728 Clinical Chemistry | 1,552 | 532 | $13.33 | $21K |
| 88185 Surgical Pathology Examination | 1,247 | 50 | $19.77 | $25K |
| 83615 Clinical Chemistry | 829 | 400 | $5.90 | $4,889 |
| 85045 Blood Count | 431 | 214 | $3.91 | $1,685 |
| 82664 Immunoassay | 307 | 124 | $59.32 | $18K |
Medicare prescription drug claims, 2024
In 2024, the drug Ravi D Rao prescribed most often to Medicare patients was Eliquis (Apixaban), with 158 prescriptions and refills. In total Ravi D Rao wrote 2,244 Medicare prescriptions that cost $7.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 158 | 183 | 23 | $108K |
| Prednisone Generic | 151 | 207 | 47 | $590 |
| Anastrozole Generic | 95 | 204 | 31 | $1,644 |
| Ondansetron Odt Ondansetron | 82 | 82 | 55 | $1,794 |
| Levothyroxine Sodium Generic | 74 | 192 | 24 | $1,059 |
| Pomalyst Pomalidomide | 57 | 57 | Under 11 | $1.1M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 54 | 54 | 27 | $1,391 |
| Prochlorperazine Maleate Generic | 51 | 53 | 47 | $1,097 |
| Hydroxyurea Generic | 43 | 71 | 13 | $1,214 |
| Valacyclovir Valacyclovir Hcl | 37 | 87 | 12 | $1,333 |
| Abiraterone Acetate Generic | 37 | 37 | Under 11 | $24K |
| Venclexta Venetoclax | 36 | 36 | Under 11 | $417K |
| Dexamethasone Generic | 35 | 70 | 20 | $696 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 32 | 36 | 25 | $94.49 |
| Jakafi Ruxolitinib Phosphate | 32 | 32 | Under 11 | $627K |
Brand drugs: 729 claims; generic drugs: 1,515 claims; opioid claims: 87.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ravi D Rao $655 ($655 in general payments such as food, travel and fees) from 15 companies. The largest payer was SpringWorks Therapeutics, Inc. with $116.
| Company | Payments | Amount |
|---|---|---|
| SpringWorks Therapeutics, Inc. | 4 | $116 |
| Exelixis Inc. EXEL | 4 | $115 |
| Abbvie Inc. ABBV | 4 | $92.61 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $53.08 |
| Celgene Corporation BMY | 2 | $39.08 |
| Array Biopharma Inc PFE | 2 | $35.24 |
| Janssen Biotech, Inc. JNJ | 1 | $29.04 |
| Pfizer Inc. PFE | 1 | $28.83 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $26.07 |
| Lilly USA, LLC LLY | 1 | $22.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.